Assessment of Health Economics in Alzheimer’s Disease (AHEAD)Treatment with Galantamine in Sweden

被引：0
|
作者：
Frances B. Garfield
Denis Getsios
J. Jaime Caro
Anders Wimo
Bengt Winblad
机构：
[1] Caro Research Institute,Division of General Internal Medicine, Royal Victoria Hospital
[2] Caro Research,Division of Geriatric Medicine
[3] McGill University,undefined
[4] Neurotec,undefined
[5] Karolinska Institutet,undefined
来源：
PharmacoEconomics | 2002年 / 20卷
关键词：
Nursing Home; Rivastigmine; Tacrine; Galantamine; Nursing Home Care;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: Like other developed countries with aging populations, Sweden is expecting large increases in the prevalence of Alzheimer’s disease and corresponding escalations in the cost of care for patients with this disease. Galantamine, a new acetylcholinesterase inhibitor and nicotinic modulator, has proved effective in managing patients with Alzheimer’s disease in clinical trials.
引用
收藏
页码：629 / 637
页数：8
相关论文
共 50 条
  • [41] A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease
    Wilcock, G
    Howe, I
    Coles, H
    Lilienfeld, S
    Truyen, L
    Zhu, Y
    Bullock, R
    DRUGS & AGING, 2003, 20 (10) : 777 - 789
  • [42] Efficacy of galantamine in treatment of Alzheimer's disease: an update meta-analysis
    Zhang, Xiaoli
    Shao, Junhui
    Wei, Yawei
    Zhang, Hui
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (04): : 7423 - 7430
  • [43] Development of Reminyl® (galantamine), a novel acetylcholinesterase inhibitor, for the treatment of Alzheimer's disease
    Parys, W
    ALZHEIMERS REPORTS, 1998, 1 : S19 - S20
  • [44] Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease
    Vellas, B
    Cunha, L
    Gertz, HJ
    De Deyn, PP
    Wesnes, K
    Hammond, G
    Schwalen, S
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (09) : 1423 - 1429
  • [45] Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease
    Seltzer, Ben
    CLINICAL INTERVENTIONS IN AGING, 2010, 5 : 1 - 6
  • [46] A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer’s Disease
    Gordon Wilcock
    Ian Howe
    Hilary Coles
    Sean Lilienfeld
    Luc Truyen
    Young Zhu
    Roger Bullock
    Paul Kershaw
    Drugs & Aging, 2003, 20 : 777 - 789
  • [47] New therapeutics for the treatment of Alzheimer's disease:: Challenges ahead
    König, G
    Ebert, U
    Baumann, K
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2002, 365 : R2 - R2
  • [48] Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease
    Small, G
    Erkinjuntti, T
    Kurz, A
    Lilienfeld, S
    CNS DRUGS, 2003, 17 (12) : 905 - 914
  • [49] Galantamine in the Treatment of Cognitive Decline in Patients with Vascular Dementia or Alzheimer’s Disease with Cerebrovascular Disease
    Gary Small
    Timo Erkinjuntti
    Alexander Kurz
    Sean Lilienfeld
    CNS Drugs, 2003, 17 : 905 - 914
  • [50] Galantamine for the Treatment of BPSD in Thai Patients With Possible Alzheimer's Disease With or Without Cerebrovascular Disease
    Tangwongchai, S.
    Thavichachart, N.
    Senanarong, V.
    Poungvarin, N.
    Phanthumchinda, K.
    Praditsuwan, R.
    Nidhinandana, S.
    Chankrachang, S.
    AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS, 2008, 23 (06): : 593 - 601
12345